Insulin Aspart (Novolog) Pharmacology Podcast Episode 312

Insulin Aspart, a rapid-acting insulin used for type 1 and type 2 diabetes, requires precise administration and monitoring to mitigate significant clinical risks. While Novolog and Fiasp are both rapid-acting, Fiasp’s vitamin B3-enhanced formulation provides a faster onset, necessitating distinct mealtime administration protocols. Because insulin is a high-alert medication, clinicians must guard against tenfold dosing errors and avoid inappropriate practices like sliding scale monotherapy, which increases hypoglycemia risk. Key adverse effects include hypoglycemia, weight gain, and hypokalemia due to intracellular potassium shifts. Effective management involves rotating injection sites to prevent lipoatrophy and monitoring blood glucose levels, particularly when patients initiate new medications like corticosteroids, which cause hyperglycemia, or antibiotics, which may alter metabolic stability. Adhering to individualized glycemic targets remains essential for optimizing patient outcomes and minimizing the danger of severe hypoglycemic events.